G. Roche-Nagle

Cyclo-oxygenase 2 inhibition potentiates anti-tumour effects of chemo/radiotherapy

ConclusionsSelective COX-2 inhibitors enhance the effects of chemo/radiotherapy and may overcome therapy-induced tumour cell resistance.

Diabetic nephropathy is ameliorated with HMG-co-enzyme A reductase treatment

ConclusionsPravastatin attenuates changes in serum creatinine, renal haemodynamics (renal flux and glomerular filtration rate [GFR]) and architectural distortion. It had no systemic effects on weight loss or serum lipid levels suggesting that reno-protection occurs locally and independent of lipid lowering.

Cyclooxygenase inhibitors reduce spontaneous metastases and serum vascular endothelial growth factor in an experimental model of breast carcinoma excision

ConclusionThis data demonstrates that selective COX-2 inhibition significantly reduces the number of spontaneous metastases in an experimental excision model of breast cancer. The authors have also shown that this may occur secondary to a reduction in the potent angiogenic factor VEGF.

Platelet and endothelial abnormalities that contribute to atherogenesis are early alterations in young male smokers

ConclusionThe above data demonstrate that the endothelial dysfunction (FMD) previously demonstrated correlates with endothelial injury (vWF) and platelet abnormalities. These are early and possibly synergistic alterations in young smokers that contribute to the development of atherogenesis.

Cyclo-oxygenase inhibition attenuates endotoxin-induced primary tumour growth and metastasis

ConclusionCOX-2 inhibitors may be of benefit in patients at risk of metastatic disease, particularly if they are also at risk of endotoxaemia.